Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of different PCV13-TT schedules in infants
ChiCTR2600124214Phase 4Recruiting
- Sponsor
- Guangxi Center for Disease Control and Prevention
- Start
- May 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Prevnar 13 in pneumococcal disease (5 arms), sponsored by Guangxi Center for Disease Control and Prevention. Primary endpoint: Serum IgG antibody levels for 13 pneumococcal serotypes. Started May 2026; status: recruiting.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ChiCTR2600124214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124214.